



# TAKHZYRO CONVERSATION STARTER

Share your answers to these questions with your doctor.

Together, you can decide if TAKHZYRO is right for you.

**1. Let's start by giving your doctor an idea of what your hereditary angioedema (HAE) is like. In the last 6 months, how many HAE attacks, or swells, have you had?**

0-3

4-6

7-9

10 or more

On a scale of 1 to 10, rate the severity of your worst HAE swell during that time:

1

2

3

4

5

6

7

8

9

10



Mild

Moderate

Severe

Now, think about how your HAE swells have affected you in the last 6 months. Be sure to share these thoughts with your doctor.

*Continued on next page*

## WHAT IS TAKHZYRO?

TAKHZYRO is a prescription medicine used to prevent attacks of hereditary angioedema (HAE) in people 2 years of age and older.

It is not known if TAKHZYRO is safe and effective in children under 2 years of age.

## IMPORTANT SAFETY INFORMATION

**TAKHZYRO may cause serious side effects, including allergic reactions.** Call your healthcare provider or get emergency help right away if you have any of the following symptoms:

- wheezing
- difficulty breathing
- chest tightness
- fast heartbeat
- faintness
- rash
- hives

Please see additional Important Safety Information throughout and full [Prescribing Information](#), including information for patients.

TAKHZYRO<sup>®</sup>  
(lanadelumab-flyo) injection

# TAKHZYRO CONVERSATION STARTER

## 2. What triggers your HAE swells? Select all that apply:

Stress                      Physical trauma                      Illness                      Physical pressure

I don't know what triggers my swells

Other:

## 3. Even if you're currently treating your HAE with a preventive medication, on-demand therapy, or both, let your doctor know how HAE is impacting you and what you'd like to change about your management plan (select all that apply):

Frequency and severity of my HAE swells

Administration method (how I take my medication)

Experience with side effects

Results I'm not currently experiencing

## 4. How important is it to have a preventive treatment with long-term study results?

Very important

Somewhat important

Important, but not as important as other qualities

*Continued on next page*

## IMPORTANT SAFETY INFORMATION (cont'd)

The most common side effects seen with TAKHZYRO were injection site reactions (pain, redness, and bruising), upper respiratory infection, headache, rash, dizziness, diarrhea, and muscle aches.

These are not all the possible side effects of TAKHZYRO. For more information, ask your healthcare provider or pharmacist. You may report side effects to FDA at 1-800-FDA-1088.

Please see additional Important Safety Information throughout and full [Prescribing Information](#), including information for patients.

  
TAKHZYRO<sup>®</sup>  
(lanadelumab-flyo) injection

# TAKHZYRO CONVERSATION STARTER

## 5. Next, tell your doctor why you're interested in TAKHZYRO. Select all that apply:

Effectiveness of TAKHZYRO

Safety profile of TAKHZYRO

Dosing: taking TAKHZYRO once every 2 or 4 weeks\*

Administration of TAKHZYRO (subcutaneous injection)

TAKHZYRO has been studied in 3 clinical trials

Over 3,250 people have been prescribed TAKHZYRO since 2018†

## 6. Now, think about your goals for reducing swells with a preventive treatment. Tell your doctor what you hope to achieve with your HAE management plan. Use the space below to organize your thoughts:

\*The recommended dose is 300 mg once every 2 weeks for people 12 years of age and older starting on TAKHZYRO. If you have zero attacks for more than 6 months, your healthcare provider may consider prescribing TAKHZYRO 300 mg every 4 weeks.

†Based on third-party US specialty pharmacy data.

## IMPORTANT SAFETY INFORMATION (cont'd)

TAKHZYRO has not been studied in pregnant or breastfeeding women. Talk to your healthcare provider about the risk of taking TAKHZYRO if you are pregnant, plan to be pregnant, are breastfeeding, or plan to breastfeed.

Please see additional Important Safety Information throughout and full [Prescribing Information](#), including information for patients.



TAKHZYRO<sup>®</sup>  
(lanadelumab-flyo) injection

©2023 Takeda Pharmaceuticals U.S.A., Inc. 300 Shire Way, Lexington, MA 02421. 1-877-TAKEDA-7 (1-877-825-3327). All rights reserved. TAKEDA and the TAKEDA logo are trademarks or registered trademarks of Takeda Pharmaceutical Company Limited. TAKHZYRO is a registered trademark of Dyax Corp., a Takeda company.

US-LANA-1294v1.0 03/23